Andrew E. Sloan, MD, FACS Neurosurgeon
Mar 9, 2023
Get to know Neurosurgeon Dr. Andrew E. Sloan, who serves patients throughout the states of Georgia, Ohio, California, Florida, and Michigan.
New York City, New York Mar 9, 2023 (Issuewire.com) - Dr. Sloan is a nationally and internationally renowned neurosurgeon, physician-scientist, & noted as one of the pioneers in the immunotherapy of brain tumors. He has had an interest in neuroscience, cancer biology, and the desire to make a difference for over three decades.
Despite his busy surgical schedule of more than 300 brain surgeries a year, he continues to be on the forefront of surgical and non-surgical treatments in neurosurgery, his expertise is in benign brain tumors, gliomas, immunotherapy, laser interstitial thermotherapy, malignant brain tumors, meningioma, minimally invasive brain surgery, spinal oncology, and tumor vaccines.
Dr. Sloan currently serves as the Chief of Neurosciences at Piedmont Healthcare in Atlanta, Georgia, where he practices as a Neurosurgical Oncologist. He also serves as Adjunct Professor of Neurological Surgery and Pathology at the Case Comprehensive Cancer Center and the Case Western Reserve University School of Medicine. From 2007-2022, Dr. Sloan served as the Peter D. Cristal Chair in Neurosurgery at University Hospitals & Vice Chairman of the Department of Neurosurgery at Case Western Reserve University School of Medicine; Director of the Brain Tumor and Neuro-Oncology Center at the Center of Excellence for Translational Neuro-Oncology, Case Comprehensive Cancer Center; Distinguished Surgeon & Senior Staff Neurosurgeon at University Hospitals Cleveland Medical Center, as well as Staff Neurosurgeon at UH Rainbow Babies & Children's Hospital.
Dr. Sloan has also served administratively on many local and national committees including the Chair of the Neuroscience Clinical Guidance Council at Piedmont Health, as well as the Neuroscience Chair of the Piedmont Research Institute.
Nationally, he has led educational and training courses on advanced neurosurgical techniques for practicing neurosurgeons and advanced trainees at both the American Association of Neurological Surgery (AANS) and the Congress of Neurosurgery (CNS). He has also served on many national committees including the Neurosurgery Committee of the NCI-funded NRG consortium; the Panel on Musculoskeletal Imaging of the American College of Radiology; and on serves on the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) at the Center for Medicare/Medicaid Services (CMS). At University Hospitals of Cleveland, he served as the Director of the Cord Compression Steering Committee, the Budget & Finance Committee, the Quality Committee, and on the Physician Advisory Board.
Driven by a lifelong desire to become a physician, Dr. Sloan graduated from Yale University, with a Bachelor of Science degree in Biology, magna cum laude, and earned his MD from Harvard Medical School. He served his internship in general surgery, and residency in neurosurgery, as well as a research fellowship at the UCLA School of Medicine. He subsequently completed a fellowship in neurosurgical oncology & skull-base neurosurgery at the MD Anderson Cancer Center in Houston, Texas. In 2020, Dr. Sloan earned his Master of Business Administration (with healthcare specialization) from Baldwin Wallace University. He is board-certified in neurosurgery by the American Board of Neurological Surgery (ABNS).
Active in local and national organizations, Dr. Sloan is a member of the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, A fellow of the American College of Surgeons (FACS), the American College of Surgeons Oncology Group, the American Academy of Neurosurgery, the AANS/CNS Spine Section, the American Society of Clinical Oncology, the Society of Neuro-Oncology, the American Society for Therapeutic Radiation Oncology, the American Association for Cancer Research, the Georgia Neurosurgical Society, the American Association for the Advancement of Science, the International Society for Biological Therapy of Cancer, the National Association for the Advancement of Colored People, the Ohio State Medical Association, and the Ohio State Neurosurgical Society (of which he is Chair Emeritus).
As a recognized leader in neurosurgery, he has served on the FDA Committee for Drugs and Devices, as well as numerous committees of the American Association of Neurosurgery including the AANS Founder's Club, the Scientific Program Committee, the Coding & Reimbursement Committee, the Executive Council for Drugs and Devices Committee, as well as a mentor of the Resident Mentoring Program.
Among his other activities, Dr. Sloan has served as a member or moderator of the Annual Scientific Meeting at AANS/CNS Joint Sections on Tumors; the Appropriateness Criteria Committee of the American College of Radiology; the Skeletal Metastasis Guidelines at the American College of Radiology; the Atlanta Chapter of the American College of Surgeons; the Bone Metastasis Panel of the American Radium Society; the Editorial Board of Operative Neurosurgery; a Founding member of the Glioma Longitudinal Analysis (GLASS) Consortium; the Ezekiel Hershey Council at Harvard Medical School; the Catalyst Council of the New England Journal of Medicine; the Neurosurgical and Brain Tumor Committees of the Radiation Therapy Oncology Group (RTOG); a Founding member of the Society for Melanoma Research; and a mentor of the Young Investigator Committee of the Society for Neuro-Oncology.
The Associate Editor of Operative Neurosurgery, Dr. Sloan also serves on the following editorial board of several neurosurgical and scientific journals, including: Acta Neuropathologica (Ad Hoc), AANS Neurosurgery Newsletter, Annals of Surgical Oncology (Ad Hoc), BMC Neurology (Ad Hoc), Brain (Ad Hoc), Cancer (Ad Hoc), Clinical Cancer Research (Ad Hoc), Cancer Immunology and Immunotherapy (Ad Hoc), Cancer Management and Research (Ad Hoc), Cancer Research (Ad Hoc), Case Reports in Medicine (Ad Hoc), Clinical Cancer Research (Ad Hoc), Frontiers in Immunology (Ad Hoc), Human Immunology (Ad Hoc), Journal of Clinical Investigation (Ad Hoc), Journal of Clinical Oncology (Ad Hoc), Journal of Immunotherapy (Ad Hoc), Journal for Immunotherapy of Cancer (Ad Hoc), Journal of Neurology, Psychiatry and Neurosurgery (Ad Hoc), Journal of the Neurological Sciences (Ad Hoc), Journal of Neuroscience (Ad Hoc), Journal of Neurosurgery (Ad Hoc), Melanoma Research (Ad Hoc), Nature: Scientific Reports (Ad Hoc), Neurological Research, (Ad Hoc), Neurosurgery (Ad Hoc), Neuro-Oncology (Ad Hoc), New England Journal of Medicine, Oncotarget (Ad Hoc), Plos One (Ad Hoc), Select Review in Neuro-Oncology (Ad Hoc), Neuro-Oncology (Ad Hoc), and World Neurosurgery (Ad Hoc).
Throughout his extensive career, Dr. Sloan has authored more than 240 peer-reviewed publications, holds 6 US patents and INDs, and more than 650 invited presentations. He also appears regularly on local, regional and national news broadcasts as a brain cancer expert.
In recognition of his commitment to medicine, Dr. Sloan has been recognized as one of the "Best Doctors in America" since 2003, a Castle-Connolly Top Doctor since 2004, and sited as one of the "Top Surgeons in America" since 2007.
By advancing brain cancer research and surgical techniques, he hopes to help people suffering from these conditions live as many good years as possible.
Learn More about Dr. Andrew E. Sloan Through his findatopdoc profile, https://www.findatopdoc.com/doctor/1639429-Andrew-Sloan-Neurosurgeon, through his website, https://www.andrewesloanlab.com/ or through Case Western Reserve University School of Medicine, https://case.edu/medicine/neurosurgery/meet-our-team/faculty/andrew-e-sloan
About FindaTopDoc.com
FindaTopDoc is a digital health information company that helps connect patients with local physicians and specialists who accept your insurance. Our goal is to help guide you on your journey towards optimal health by providing you with the know-how to make informed decisions for you and your family.
Source :Andrew E. Sloan, MD, FACS
This article was originally published by IssueWire. Read the original article here.
More News
The next beauty conversation isn't about skin, it's about your scalp
Target Pro by Watsons is proof that consumers are becoming more discerning, as the brand celebrates its 10th anniversary. The positive consumer response and influencer reviews of its consumer-focused anniversary activations and promotions demonstrate that people increasingly value science-backed, targeted solutions developed through Japanese innovation. The brand's continued success inspires the development of new products that address the evolving needs of its consumers. In line with its anniversary celebration, Target Pro by Watsons introduces Femtech Lab, a breakthrough hair care line that puts the spotlight on the scalp, recognizing that it needs as much care as the face and the rest of the body. Femtech Lab believes that the secret to healthy hair starts with a healthy scalp. Femtech Lab addresses women's health and beauty needs through AI-powered screening technology and laboratory expertise. Its advanced scalp care solutions cater to four scalp types: dry, oily, thinning-prone and sensitive. Femtech Lab offers products designed to address how changing needs and everyday factors, from hormonal shifts to environmental conditions, influence scalp and hair health. The brand also targets specific concerns, including stress-induced hair problems and postpartum hair loss. Its formulations aim to simplify scalp and hair care routines while providing targeted solutions. Like Target Pro by Watsons, Femtech Lab delivers reliable solutions developed through scientific and dermatological studies by Japanese experts. Femtech Lab offers four flagship products designed to care for hair from scalp to tip: Anti-Hair Fall Root Balance Scalp Serum (P1,199), Anti-Hair Fall Root Renew Scalp Serum (P1,199), Anti-Hair Fall & Clarifying Shampoo (P899), and Anti-Hair Breakage & Shining Conditioner (P899). The Anti-Hair Fall Root Balance Scalp Serum is clinically proven to reduce hair fall and scalp sebum while improving hair density in four weeks. It features the trademarked ingredients ScalpZen and Prunizen, which help address scalp concerns and promote stronger, fuller and thicker-looking hair. For those looking to promote hair growth and address graying hair, the Anti-Hair Fall Root Renew Scalp Serum offers another targeted solution. Formulated with Baicapil and Kerascalp, it promises visible results after 12 weeks of consistent use. Reset your scalp with the Anti-Hair Fall & Clarifying Shampoo, which features a clarifying and rebalancing formula. It contains salicylic acid, panthenol and niacinamide to help provide long-lasting oil control and improve hair volume. The Anti-Hair Breakage & Shining Conditioner complements the shampoo by helping strengthen and protect hair. It enhances scalp comfort while improving hair condition from root to tip. The formula also helps increase moisture, smoothness and shine. As with Target Pro by Watsons, consumers can turn to Femtech Lab for targeted and effective hair and scalp care. Its approach highlights the value of Japanese science-led expertise, focusing not only on surface-level aesthetics but also on formulations designed to nourish the scalp and hair. Femtech Lab represents the natural evolution of Target Pro by Watsons' mission to provide comprehensive skin and beauty care, recognizing that targeted solutions go beyond the face. It also reflects the brand's continued evolution and commitment to addressing women's changing beauty and wellness needs through targeted, science-led innovation. Discover Target Pro by Watsons' Femtech Lab products, available at Watsons branches nationwide and through the Watsons app. Learn more about incorporating targeted scalp and hair care into your routine with Target Pro by Watsons and Femtech Lab.
Dole launches 24/7 hotline for El Niño-related work concerns
MANILA, Philippines — The Department of Labor and Employment (Dole) has launched a new hotline called 15/30, as part of preparations for the El Niño phenomenon, which is expected to intensify this month until March next year. The nationwide hotline serves as a 24/7 help desk through which workers and their employers may raise job-related
![[In the Public Square] US elections: What’s at stake](https://www.rappler.com/tachyon/2026/11/In-the-Public-Square-LS-SQ.jpg)
[In the Public Square] US elections: What’s at stake
What are some of the highlights of an election that is consequential for the rest of the world?
Latest DPWH stink: P491-M ‘right-of-way scam’; 6 face graft raps
MANILA, Philippines — The Office of the Ombudsman on Tuesday filed graft and malversation charges in the Sandiganbayan against six former Department of Public Works and Highways (DPWH) officials over their alleged involvement in the irregular acquisition of road right-of-way (ROW), worth at least P491 million, in General Santos City. The Ombudsman said it found
Palace to police chief: Get Dela Rosa despite PNP past
MANILA, Philippines — Malacañang challenged the leadership of the Philippine National Police on Tuesday to ensure that Sen. Ronald “Bato” dela Rosa’s past position as PNP chief during the Duterte administration would not stand in the way of operations to serve him the arrest warrant issued by the International Criminal Court (ICC). Palace press officer
LTFRB fines Move It P555.75M over excess rider-partners
MANILA, Philippines — The Land Transportation Franchising and Regulatory Board (LTFRB) has imposed a P555.75-million penalty on motorcycle taxi platform Move It for exceeding its authorized number of rider-partners. Move It was authorized to operate only 17,746 rider-partners across Metro Manila, Cebu City, and Cagayan de Oro, but it exceeded this limit by 55,575 riders,
ERC issues show cause orders vs. 13 power firms over outages in Visayas, Mindanao
The Energy Regulatory Commission (ERC) has issued 24 show-cause orders (SCO) against 13 power generation companies over power outages that hit the Visayas and Mindanao.
M2M wanted a better ending. They found a new beginning
With their friendship rekindled, Marit Larsen and Marion Raven went on tour—and are returning to Manila for more
Palace: Budget red flags can lead again to Marcos veto
MANILA, Philippines — President Ferdinand Marcos Jr. will not hesitate to exercise his veto power to remove questionable allocations from the proposed P7.2-trillion national budget for 2027, Malacañang said on Tuesday, after civil society watchdogs flagged more than P1 trillion in allegedly irregular spending and pork-barrel items in the House-approved version of the measure. Palace
/file/publisher-c1a3f893382d2b2f8a9aa22a654d9c97/2022/12/320feb3ceaa2ab1e4f4280e5bb46dc8e.jpg)
Hidden charges when ordering food: Minister says it's against the law
Armizan says full enforcement will begin in January, warns traders and relevant parties.
Biz group to DOTr: Don’t open busway to private cars
MANILA, Philippines — The Management Association of the Philippines (MAP) is pushing back against the Department of Transportation’s (DOTr) decision to temporarily allow private cars on the Edsa Busway, saying this would defeat the project’s very purpose. “Dedicated bus roadway and only regulated buses with high-volume capacity are the design imperatives for the Busway,” the
BARMM chief minister speeds up Cabinet formation
COTABATO CITY, BARMM, Philippines — Bangsamoro Chief Minister Abdulraof “Sammy Gambar” Macacua has given the selection committee for top positions in the Bangsamoro government until 5 p.m. today to submit the possible appointees to his Cabinet. The positions to be filled include at least 15 ministers and deputy ministers, and a number of heads of
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.